Akorn Stock Price and Value Analysis

Should you buy Akorn stock? (NasdaqGS:AKRX). Let's see how it does in our automated value investing analysis system.

AKRX Free Cash Flow Trend

Free Cash Flow trendline for AKRX
Free Cash Flow trendline for Akorn

Hmm, we can't give any reliable projection for Akorn's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

  • This company is solid.
  • This stock looks overpriced.
  • This company is not making money.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the AKRX Numbers

AKRX Price
(Akorn stock price per share)
[?] PE Ratio versus Sector 59% higher than other Healthcare stocks
[?] PE Ratio versus Industry 35% lower than other Drug Manufacturers - Specialty & Generic stocks
[?] Cash Yield 32.34%
[?] Free Cash Flow Jitter 335%

Is Akorn Stock on Sale?

Based on our analysis, we believe that you should not buy Akorn right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy AKRX Stock?

Does Akorn have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.